Purchase this article with an account.
B. A. Aird, G. A. Baklayan, C. K. Song, J. A. Gow; A Comparison of the Settling and Particle Size Characteristics for T-PredTM, Tobradex®, and ZyletTM Ophthalmic Suspensions. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1061.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the settling and particle size characteristics of ophthalmic suspensions; T-PredTM (prednisolone acetate 1.0% and tobramycin 0.3%, pending FDA approval), Tobradex® (dexamethasone 0.1% and tobramycin 0.3%), and ZyletTM (loteprednol etabonate 0.5% and tobramycin 0.3%).
The particle size of all three suspension products was measured using a Beckman Coulter LS 13 320 particle size analyzer equipped with a universal liquid module. Particle size measurements were taken before and after sonication to break up any aggregates. Settling rates for all three products were compared by dispensing into test tubes and vortexing, followed by visual inspection and photo-documentation periodically for 24-hours.
T-PredTM exhibited a tighter particle size distribution and a smaller average particle size than either ZyletTM or Tobradex®. The mean particle size for T-PredTM, ZyletTM, and Tobradex® before sonication was 1.2 µm, 3.5 µm, and 2.4 µm respectively and 0.6 µm, 2.4 µm, and 2.4 µm respectively after sonication. Over a period of 24-hours, T-PredTM also exhibited slower settling rates compared to the other two products.
T-PredTM exhibited a tighter particle size distribution and a smaller average particle size than either ZyletTM or Tobradex®. When compared to either ZyletTM or Tobradex®, T-PredTM also demonstrated substantially less settling.
This PDF is available to Subscribers Only